Results 141 to 150 of about 618,618 (261)

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

9-1-1 Call Data Modeling to Assess the Influence of a Mass Gathering on Host Community Metrics for Syndromic Surveillance. [PDF]

West J Emerg Med
Yancey AH, Robinson E, McMahan T, Cotsonis GA.   +3 more
europepmc   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

OH-MEMA: An Integrated One Health Mixed-Effects Modeling Approach for Syndromic Surveillance. [PDF]

J Clin Med
Basheer A, Khiabani PM, Jentner W, Wendelboe A, Vogel JR, Kuhn KG, Wimberly MC, Hougen D, Ebert D.   +8 more
europepmc   +1 more source

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

BMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng, Yunfei Sha, Jiongyan Yang, Hongru Yang, Xiao Liang   +4 more
wiley   +1 more source

Applying the Moving Epidemic Method to Emergency Department Syndromic Surveillance to identify the Start of Influenza Seasons in New South Wales, Australia. [PDF]

Influenza Other Respir Viruses
Rose N, Craig AT, Muscatello DJ.
europepmc   +1 more source

Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and
Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon   +6 more
wiley   +1 more source

Leveraging Syndromic Surveillance for Rabies Postexposure Prophylaxis Surveillance in Maine, 2018-2022. [PDF]

Public Health Rep
Lamere L, Sohail H, Robinson S.
europepmc   +1 more source